Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors

Population Pharmacokinetics ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Her2 Positive ◽

PI-13Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors

Clinical Pharmacology & Therapeutics ◽

10.1016/j.clpt.2005.12.034 ◽

2006 ◽

Vol 79 (2) ◽

pp. P10-P10 ◽

Cited By ~ 2

Author(s):

F GUO ◽

S LETRENT ◽

D NOE ◽

A QIN ◽

K ROHRBACHER ◽

...

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Her2 Positive ◽

PII-70A population pharmacokinetic analysis of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors

Clinical Pharmacology & Therapeutics ◽

10.1016/j.clpt.2005.12.195 ◽

2006 ◽

Vol 79 (2) ◽

pp. P54-P54

Author(s):

F GUO ◽

S LETRENT ◽

A SHARMA

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Population Pharmacokinetic Analysis ◽

Pharmacokinetic Analysis ◽

Population Pharmacokinetic ◽

Her2 Positive ◽

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-007-0579-4 ◽

2007 ◽

Vol 62 (1) ◽

pp. 97-109 ◽

Cited By ~ 10

Author(s):

Feng Guo ◽

Stephen P. Letrent ◽

Pamela N. Munster ◽

Carolyn D. Britten ◽

Karen Gelmon ◽

...

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Clinical Characteristics ◽

Kinase Inhibitor ◽

Her2 Positive ◽

Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.

10.1158/0008-5472.sabcs-09-5060 ◽

2009 ◽

Cited By ~ 18

Author(s):

T. Hickish ◽

D. Wheatley ◽

N. Lin ◽

L. Carey ◽

S. Houston ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Her2 Positive ◽

Bibw 2992 ◽

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer

Cancer Management and Research ◽

10.2147/cmar.s321428 ◽

2021 ◽

Vol Volume 13 ◽

pp. 7165-7174

Author(s):

Ying Sun ◽

Beibei Chen ◽

Jisheng Li ◽

Ling Peng ◽

Shuguang Li ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Tyrosine Kinase ◽

Real World ◽

Kinase Inhibitor ◽

Metastatic Breast ◽

Efficacy And Safety ◽

Her2 Positive ◽

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

Investigational New Drugs ◽

10.1007/s10637-021-01093-7 ◽

2021 ◽

Author(s):

Katrina S. Pedersen ◽

Patrick M. Grierson ◽

Joel Picus ◽

A. Craig Lockhart ◽

Bruce J. Roth ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Kinase Inhibitor

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-11-2378 ◽

2011 ◽

Vol 18 (4) ◽

pp. 1092-1100 ◽

Cited By ~ 50

Author(s):

Adil I. Daud ◽

Smitha S. Krishnamurthi ◽

Mansoor N. Saleh ◽

Barbara J. Gitlitz ◽

Mitesh J. Borad ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Abl Tyrosine Kinase ◽

Abl Tyrosine Kinase Inhibitor

Abstract A108: A phase I and pharmalogical study of the broad‐spectrum tyrosine kinase inhibitor JNJ‐26483327, administered to subjects with advanced or refractory solid tumors

10.1158/1535-7163.targ-09-a108 ◽

2009 ◽

Author(s):

Inge R. Konings ◽

Maja J. de Jonge ◽

Herman Burger ◽

Ate van der Gaast ◽

Ludy EC van Bijsterveld ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Solid Tumors ◽

Broad Spectrum ◽

Kinase Inhibitor

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Cancer Research and Treatment ◽

10.4143/crt.2017.303 ◽

2018 ◽

Vol 50 (3) ◽

pp. 835-842 ◽

Cited By ~ 24

Author(s):

Tae Min Kim ◽

Keun-Wook Lee ◽

Do-Youn Oh ◽

Jong-Seok Lee ◽

Seock-Ah Im ◽

...

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Phase 1 ◽

Advanced Solid Tumors

Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714

Toxicological Sciences ◽

10.1093/toxsci/kfp033 ◽

2009 ◽

Vol 108 (2) ◽

pp. 492-500 ◽

Cited By ~ 55

Author(s):

Bo Feng ◽

Jinghai J. Xu ◽

Yi-An Bi ◽

Rouchelle Mireles ◽

Ralph Davidson ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Hepatic Transporters ◽